|
Sep 14, 2022
|
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
|
|
|
Sep 06, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Aug 31, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Aug 31, 2022
|
FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
|
|
|
Aug 26, 2022
|
BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients
|
|
|
Aug 25, 2022
|
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
|
|
|
Aug 18, 2022
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
|
|
|
Aug 04, 2022
|
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
|
|
|
Aug 04, 2022
|
BioCryst Resumes Enrollment in BCX9930 Clinical Program
|
|
|
Jul 21, 2022
|
BioCryst to Report Second Quarter 2022 Financial Results on August 4
|
|
